AI in Medicine News — 2026-10-14 (Wed) Morning News

Overview

Activity centered on clinical decision support, medical documentation and hospital operations, with AI-assisted imaging and diagnostic evaluations also reported (Imaging Technology News, STAT, Fierce Healthcare, TechTarget). In drug discovery, headlines covered funding and startup programs, and one on virtual cells for target discovery (Digital Health News, Konsulteer, Scientist Live). On regulation, one item concerned a US FDA generative AI proposal. Several items called for real-world evaluation and guardrails (Medical Device Network, Rediff, Medscape).

Diagnostics and imaging

- An MRI study reports that AI could help avoid prostate biopsies. The headline gives no performance figures, and the evidence is at the study level (Imaging Technology News). - STAT published takeaways from an evaluation of Google's diagnostic chatbot, AMIE. The headline does not state the results (STAT). - A Health Policy Institute (HPI) item says evidence contradicts broad claims about AI and the radiology workforce (AuntMinnie). - Agilent is to acquire Proscia, described as advancing AI-enabled digital pathology and scientific intelligence. This is a corporate transaction, not clinical evidence (BioSpace). - Experts say AI can aid faster, cost-effective diagnosis, but clinical validation and data safeguards are needed (The Hindu).

Clinical decision support

- A Nature piece discusses the value of the "divergence event" in clinical human-AI interaction (Nature). - An AI model maps complication risk in type 1 diabetes. The headline gives no accuracy figures or validation stage (Medscape). - IGC Pharma unveiled the PRISM AI platform, positioned to move Alzheimer's risk prediction toward brain-health action and commercial deployment. This is a company announcement, and no validation data are given in the headline (Morningstar). - OpenEvidence and Johns Hopkins Medicine are partnering on AI in medical education and clinical care (Unite.AI, Fierce Healthcare). 【Generative AI and medical documentation / records】 - Modern Healthcare reports that AI could make it harder to switch EHR vendors (Modern Healthcare). - EHR interoperability gaps threaten to limit AI's potential (TechTarget). - Suki raised $90 million in Series E financing to expand its healthcare AI platform (citybiz). - Medsender launched agentic referral management for specialty practices. The company claims they turn 4.8x more referrals into appointments, a vendor claim with no independent evidence cited in the headline (citybiz). 【Hospital operations and care delivery】 - UT Austin is building more than a hospital, and the article covers where AI comes in (Austin American-Statesman). - A 2026 HCD Conference + Expo preview covers using AI to optimize design decisions and improve outcomes (Healthcare Design Magazine). - Wound Care Advantage launched Luvo Assist, described as the first AI-assisted mission control for hospital wound care, outpatient and inpatient (The Globe and Mail). - Experts stress real-world AI evaluation for safe healthcare deployment (Rediff). - A separate item states that operating models will define competitive advantage as AI becomes standard. The headline does not mention healthcare specifically (Hotel News Resource). 【Drug discovery and clinical trials】 No headline in this batch gives a clinical phase (preclinical, Phase I and so on). - GenScript and NVIDIA launched PitchFest for AI-driven drug discovery startups (Konsulteer). - Shift Bioscience's new research increases confidence in AI virtual cells for novel target discovery. This is target discovery, an early research stage (Scientist Live). - The Ministry of Science committed INR 86 Cr to Peptris for AI-based drug development. The development stage is not given (Digital Health News). - Simeon George of SR One argues that AI's real biotech payoff is early development rather than late-stage prediction. A related Business of Biotech item covers AI, China and biotech investing (BigGo Finance, finance.biggo.com). 【Medical device approval / regulation】 - The FDA's generative AI proposal is described as evolving regulation for an evolved medtech era. It is a proposal, not an approval, designation or finalized guidance, and no product name is given (Medical Device Network). - A Cureus article covers AI-enabled pharmacovigilance for neuropsychiatric therapies, in the context of US drug safety surveillance and regulatory decision-making. It is a journal article, not a regulatory action (Cureus).

Safety, errors and bias

- The Hastings Center raises ethical questions that arise when medical AI works well (The Hastings Center for Bioethics). - Privacy-preserving training could expand medical AI for children while keeping data local. The headline says "could", so the evidence is at the research stage (Medical Xpress). - Browne Jacobson uses the London Tube map to discuss AI in healthcare (Browne Jacobson). - European experts urge guardrails for AI in medicine (Medscape). 【Research results (major journals)】 - A Nature paper reports human-AI collaboration for comanaging epilepsy in real time. The headline gives no performance figures (Nature). - A Lancet study states that "Malicious Use" of AI and nuclear war pose an extinction threat to humanity this century. It concerns existential risk, not clinical care (Common Dreams, Daily Asian Age). - A Nature scoping review of 806 studies across 62 languages examines linguistic inequity in clinical AI evaluation (Nature). - AI screening helps more people with diabetes access sight-saving eye care. The headline gives no figures or study design (Medical Xpress).

Developments in Japan

- Big MY and an overseas literature service are offering a support service for pharmaceutical companies that uses "AI persona physicians" (d Menu News). - OpenEvidence and Johns Hopkins Medicine are partnering on medical education and care in the AI era, the same item covered in section 3 (Unite.AI). - The other Japanese-language items concern AI security testing, AI usage log diagnostics and enterprise AI pilots (GMO Flatt Security via PR TIMES, Infoseek, BigGo Finance). Their headlines contain no medical content.

Statements by key figures

- Simeon George, M.D., of SR One: AI's real biotech payoff is early development, not late-stage prediction. The tracked-person list was empty, and the title is not given beyond the SR One affiliation (BigGo Finance). - Lai (title not stated in the headline) highlighted the role of physical therapy and AI in healthcare (Taipei Times).